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ABSTRACT  55 
Purpose:  56 
Conventional techniques (3D-CRT) for craniospinal irradiation (CSI) are still widely used.  57 
Modern techniques (IMRT, VMAT, TomoTherapy®, proton pencil beam scanning [PBS]) are 58 
applied in a limited number of centers.  59 
For a 14-year old patient, we aimed to compare dose distributions of five CSI techniques 60 
applied across Europe and generated according to the participating institute protocols, 61 
therefore representing daily practice.    62 
Material & Methods:  63 
A multicenter (n=15) dosimetric analysis of five different techniques for CSI (3D-CRT, IMRT, 64 
VMAT,  TomoTherapy®, PBS; 3 centers per technique) was performed using the same 65 
patient data, set of delineations, and dose prescription (36.0/1.8Gy). Different treatment 66 
plans were optimized based on the same planning target volume margin. All participating 67 
institutes returned their best treatment plan applicable in clinic. 68 
Results:   69 
The modern radiotherapy techniques investigated resulted in superior 70 
conformity/homogeneity-indices (CI/HI), particularly in the spinal part of the target (CI: 3D-71 
CRT:0.3 vs. modern:0.6; HI: 3D-CRT:0.2 vs. modern:0.1), and demonstrated a decreased 72 
dose to the thyroid, heart, esophagus, and pancreas. Dose reductions of >10.0Gy were 73 
observed with PBS compared to modern photon techniques for parotid glands, thyroid, and 74 
pancreas. Per technique, a  wide range in dosimetry among centers using the same 75 
technique was observed (e.g. thyroid mean dose: VMAT: 5.6–24.6Gy; PBS: 0.3–10.1Gy). 76 
Conclusions:  77 
The investigated modern radiotherapy techniques demonstrate superior dosimetric results 78 
compared to 3D-CRT. The lowest mean dose for organs at risk is obtained with proton 79 
therapy. However, for a large number of organs ranges in mean doses were wide and 80 
overlapping between techniques making it difficult to recommend one radiotherapy 81 
technique over another.  82 
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91 
INTRODUCTION 92 
Craniospinal irradiation (CSI) is indicated for medulloblastoma and some rarer tumors with 93 
signs of leptomeningeal spread, particularly germ-cell tumors, atypical teratoid rhabdoid 94 
tumors, and ependymomas [1-8].  95 
The technique most commonly used for treating the craniospinal axis is a combination of 96 
two lateral opposed photons beams for the brain, matched to one or more posterior photon 97 
fields to treat the spine [9,10]. This approach results in dose inhomogeneity, especially at 98 
the beam junction(s), and a significant dose anterior to the spinal target volume. Over the 99 
last decade, other techniques for CSI have been investigated in order to decrease the dose 100 
to the organs outside the target volume, in particular the thyroid, heart, and intestines [11-101 
15]. Intensity-Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy 102 
(VMAT), and  TomoTherapy® are highly conformal techniques which can reduce the dose to 103 
the structures anterior to the vertebrae at the expense of a larger volume of low-dose 104 
irradiation to the entire body. Due to the steep dose gradient, both electron and proton 105 
beam radiation provide substantial sparing of non-target tissues anterior to the spinal target 106 
volume compared to photons [16,17].  107 
In clinical practice, the reason for using more conformal techniques is better sparing of 108 
healthy tissue. However, the vast majority of late effects reported after CSI in childhood 109 
arise from irradiation of the target volume [18-21]. Dose and age influence toxicity outcome 110 
and are the justification for dose reduction, altered fractionation regimens, a combination 111 
with systemic agents or target volume adaptations [22-26]. Further decrease of late 112 
toxicity, e.g. second malignancies outside the target volume, primary hypothyroidism, 113 
cardiovascular events, restrictive lung disease, and metabolic syndrome might be obtained 114 
with modern radiotherapy techniques that lower the dose to the structures anterior to the 115 
vertebrae without compromising the target coverage [21,27-32].  116 
The lack of exit dose and high conformity observed with protons are potential reasons for 117 
referring patients with a CSI indication to proton therapy centers. However, when referring 118 
for proton therapy it is important to balance other factors, such as treatment delay, 119 
accessibility, associated financial issues, social disruption of the family, and secondary 120 
malignancy estimation. 121 
The question we tried to answer in this work was how radiation type and technique 122 
influences target dose coverage and OAR dose burden, and how these variables vary when 123 
such techniques are executed by different institutions.   124 
In this study we compare dose distributions of five CSI techniques currently applied across 125 
Europe, generated for a single patient and according to the participating institute protocols, 126 
therefore representing daily practice.  127 
To the authors’ knowledge,  this is the first time a CSI dose distribution comparison has 128 
been performed using the same patient data and with three different institutes plan each of 129 
the considered delivery techniques. 130 
131 
METHODS & MATERIALS 132 
A CT scan from a 14-year-old boy, previously irradiated for high-risk medulloblastoma, was 133 
selected. Approval for the study was obtained from the University Medical Center Utrecht, 134 
Research Ethics Committee.  135 
An individual head-neck support with five-point fixation mask (Civco Medical Solutions, 136 
Kalona, Iowa, USA), vacuum mattress (BlueBagTM Vacuum Cushion, Elekta, Stockholm, 137 
Sweden), and a customized knee-feet fixation (MacroMedics BV, Waddinxveen, The 138 
Netherlands) were used to scan (slice thickness 3 mm) the patient in a supine position for 139 
radiotherapy.  140 
Contouring of the clinical target volume (CTV) and organs at risk (OAR) was performed at 141 
one center (Utrecht, The Netherlands). The cranial part of the CTV comprised the entire 142 
brain, cranial nerves, and meninges. The spinal part of the CTV contained the spinal canal 143 
as observed on CT scan including the cerebrospinal fluid extension to the spinal ganglia. The 144 
inferior limit of the spinal CTV was defined by a co-registered MRI at the caudal extent of 145 
the thecal sac.  146 
The planning target volume (PTV) consisted of an uniform expansion around the CTV of 5 147 
mm for the brain (PTVbrain) and the spinal levels C1-L2 (PTVspine), and of 8 mm for the levels 148 
L3-S3 (PTVspine). PTVtotal is defined as the combination of PTVbrain and PTVspine. Outlined OARs 149 
included: scalp, left/right lenses, left/right parotid and submandibular glands, thyroid, 150 
larynx and proximal esophagus, esophagus, heart, left/right lungs, intestines and stomach, 151 
pancreas, and left/right kidneys. The total normal tissue volume (TNTV) corresponds to the 152 
external contour of the body, imaged on the CT scan, minus PTVtotal.  153 
 154 
Treatment planning 155 
The radiotherapy department of the University Medical Center Utrecht, The Netherlands, 156 
sent the CT-scan with contours to fourteen additional SIOP-E-linked institutes participating 157 
in this study. Each center used either 3D-CRT, IMRT, VMAT,  TomoTherapy® (in the 158 
following Tomotherapy), or PBS for CSI, and three centers per technique were included.  159 
Selection of participating centers was based on participation in the radiotherapy working 160 
group meeting of the SIOP-E-Brain Tumor Group and the availability to  generate a 161 
respective treatment plan for CSI. Three institutes per technique were randomly identified.  162 
All participating institutes were asked to return the best treatment plan, applicable in daily 163 
practice, for a dose prescription of 36.0 Gy in 20 fractions of 1.8 Gy, and meeting the 164 
following criteria: (1) high weighing for PTVtotal coverage (at least 95% of PTVtotal should 165 
receive 95% of the prescribed dose), and (2) maximal sparing of the OARs.  166 
An overview of the major characteristics per technique and per center is listed in Table 1.  167 
An overview of the constraints used by the centers is given in Table S1. 168 
In order to quantify inter-patient dosimetric differences on organs at risk five patients with 169 
indication for CSI, previously  irradiated at the radiotherapy department of the University 170 
Medical Center Utrecht, were re-planned using VMAT by the same planner for a dose-171 
prescription of 36.0 Gy in 20 fractions of 1.8 Gy.  172 
 173 
 174 
 175 
 176 
 177 
 178 
 179 
 180 
 181 
 182 
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Table 1. Overview of the treatment planning geometry per technique, and per center. 183 
 Center 3D-CRT IMRT VMAT Tomotherapy PBS 
TPS 1 
2 
3 
Eclipse  
Pinnacle 
 Oncentra Masterplan  
Pinnacle  
Pinnacle  
Oncentra  
Monaco  
Eclipse  
Monaco  
Tomotherapy  
Tomotherapy Tomotherapy  
Raystation  
Eclipse  
Raystation  
Dose algorithm 1 
2 
3 
AAA,  
Adaptive Convolve  
Collapsed Cone 
Collapsed cone 
Adaptive Convolve 
Collapsed cone 
Monte Carlo 
AAA 
Monte Carlo 
Convolution-superposition 
Collapsed cone 
Collapsed cone 
 Pencil beam  
Pencil beam 
Pencil beam 
Dose grid size  
(mm) 
1 
2 
3 
2 
2.5  
3 
4 
3 
2 
3  
2.5 
3 
2.15 
2.15 
2.54 
2 
2 
2 
Energy (MV) 1 
2 
3 
6, 15 
6 
6, 15 
6 
6 
6 
6 
6 
6 
6 
6 
6 
180 MeV-100 MeV  
180 MeV-100 MeV  
180 MeV – 70 MeV 
Technique 
characteristics 
 
Brain 
     1 
 
 
 
 
2 
 
 
 
 
3 
 
 
- 
 
 
 
 
Forward planned 
 
 
 
 
- 
 
 
        Forward planned 
 
 
 
 
Forward planned 
 
 
 
 
2 IMRT beams 
 
 
 
              Full arc  
 
 
 
 
Full arc  
 
 
 
 
2 partial arcs 
 
 
               Full arc 
 
 
 
 
Full arc 
 
 
 
 
Full arc 
 
 
Spot size 3 mm, range shifter 
thickness 75 mm, all MUs 
delivered with range shifter, 
airgap 300mm, robust 
optimization 
Spot size depends on depth, 
range shifter 75mm, all MU’s 
delivered with range shifter, 
airgap 20mm, robust 
optimization 
Spot size 3 mm, range shifter 
thickness 40 mm, the 
percentage of MU’s delivered 
with range shifter depends on 
beam, airgap 
300mm, single field 
optimization 
Spine 1 
2 
3 
- 
At extended ssd 
- 
Posterior fields 
Posterior fields inverse opt 
5 IMRT beams 
2 posterior partial arcs 
2 partial arcs 
3 partial arcs 
Full arc 
Full arc 
Full arc 
Same as for brain 
Same as for brain 
Same as for brain 
Number of 
isocenters 
1 
2 
3 
3 
2 
3 
3 
3 
3 
3 
3 
3 
1 
1 
1 
3 
3 
3 
Isocenter location 1 
 
2 
 
3 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic spine 
 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
- C1, thoracic/lumbar 
spine  
mid brain, thoracic/lumbar 
spine 
mid brain, thoracic/lumbar 
spine 
Beam(s) gantry 
angle* (°) 
1 
 
2 
 
 
 
 
 
3 
Brain: 85, 272 Spine: 180 
 
Brain: 90, 270 Spine: 180 
 
 
 
 
 
Brain: 85, 270 Spine: 180 
 
Brain: 90, 270 Spine: 120, 145, 
180, 215, 240  
Brain: 90, 270 Spine: 135, 180, 
225  
 
 
 
 
Brain: 90, 270 
Spine: 120, 150, 180, 210, 240 
Brain: 180.1-179.9  Spine: 180-
240 and 100-180 
Brain and spine: 180.1 – 179.9 
Avoidance sectors: thoracic 
spine: 245-320, 50-115, lumbar 
spine: 230-300, 67-130 
Brain: 180-130, 50/130 
Thoracic spine: 180-90, 90-90, 
300-120 Lumbar spine: 180-90, 
90-90, 300-120 
- Brain: 30, 330 Spine: 0 
 
Brain:30, 330 Spine : 180 
 
 
 
 
 
Brain: 180, 90 couch - 15, 270 
couch 15, Spine: 180 
Number of 
junctions 
1 
2 
3 
3 
3 
2 
2 
2 
2 
2 
2 
2 
- 2 
2 
2 
Length of junction 
in CC direction 
(cm) 
1 
2 
3 
6 
1.6 
1.5   
6 
4 
3 
8 
3  
3 
- 10 
8 
8 
Abbreviations: TPS: Treatment Planning System; CC: Cranio Caudal direction; SSD: Source-to-Skin-Distance 184 
* For VMAT the start/stop gantry angle of the arc is indicated185 
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Plan evaluation 186 
Radiotherapy treatment plans were compared per technique and each specific technique 187 
also between centers. Dose-volume histograms were evaluated for the PTVs (PTVtotal, 188 
PTVbrain and PTVspine) and the OARs. Conformity index (CI) and homogeneity index (HI) were 189 
calculated by using the van ‘t Riet formula [33] (CI: range 0-1, with 1 being highly-190 
conformal) and Kataria formula [34] (HI: range 0-1, with 1 being highly heterogeneous): 191 
CI =
V%



V
 × V%
 
 192 
 =
%
 − %


 
            193 
In the formula: V95% represents the volume receiving at least 95% of the prescribed dose; 194 
Dx% the dose received by x% of the volume of the PTV.  195 
For the TNTV the percentage of volume receiving at least 1.0, 2.0, 5.0, 34.2 and 36.0 Gy 196 
was calculated. The median and range (minimum/maximum) of each of the dosimetric 197 
parameters were computed for each technique.  198 
Superiority of the different techniques was assessed based on the highest conformity 199 
(highest CI) and homogeneity (lowest HI) for the PTV, in combination with the lowest mean 200 
dose to the OARs.   201 
For the purpose of this study, a difference between techniques is considered of “potential 202 
clinical significance” if a mean dose difference ≥5.0 Gy is observed for the OARs. This 203 
threshold is chosen based on a consensus between the participating institutes. 204 
 205 
 206 
207 
RESULTS 208 
Figure 1 represents the dose distribution in a sagittal plane for a 14-year old boy, receiving 209 
36.0 Gy by the five different radiotherapy techniques considered in this work. 210 
 211 
  212 
Figure 1. Craniospinal axis dose distribution with photons (3D-CRT, IMRT, VMAT, Tomotherapy) and protons. Only 213 
one out of three generated plans per technique is depicted.  214 
 215 
Conformity and homogeneity 216 
The median CI for the PTVtotal of all modern radiotherapy techniques was superior compared 217 
to 3D-CRT, and this was attributable to the spinal part of the target volume ( Table 2). The 218 
median HI for PTVtotal was similar for all techniques when considering the range of data per 219 
technique, however better median HI values for PTVspine were observed with modern 220 
radiotherapy techniques ( Table 2).  221 
In particular for the 3D-CRT technique, hot spots within the PTVspine (V107%: 10.6-27.1%) 222 
and absolute doses above 40.0 Gy (111 %) were observed (Table 2).  223 
The largest variation between centers using the same technique for the CI of the PTVbrain 224 
was  found for IMRT (0.8-1.0) and PBS (0.7-0.9). For  the CI of the PTVspine , largest 225 
variation was observed for VMAT (0.6-0.8), Tomotherapy (0.5-0.7) and PBS (0.5-0.7). PBS 226 
dose distributions showed the widest range in D2% (PTVbrain: 36.4-40.0 Gy; PTVspine: 36.4-227 
39.6) while VMAT dose distributions in D98% (PTVbrain: 33.7-35.5 Gy; PTVspine: 33.7-35.2 228 
Gy) (Figure 2and Table 2). 229 
 230 
Figure 2 CI, HI, D2% and D98% of the PTVbrain and PTVspine per center per technique 231 
 232 
Normal tissue sparing  233 
Compared with 3D-CRT, a decrease in the mean dose to the thyroid by more than 10.0 Gy 234 
(28.5 Gy vs. 15.1∗ Gy) was observed for all modern photon radiotherapy techniques, while a 235 
decrease between 5.0 and 10.0 Gy for the mean dose of both parotid glands (20.5 Gy vs 236 
14.9* Gy), heart (13.4 Gy vs. 8.1* Gy), esophagus (29.9 Gy vs. 20.7* Gy) and pancreas 237 
(17.1 Gy vs. 11.5* Gy) was seen (Figure 3, Table 3).  238 
With respect to modern photon techniques, PBS further reduced the mean dose to the OARs 239 
by more than 10.0 Gy for the average of both parotid glands (14.9* Gy vs. 4.0 Gy), thyroid 240 
(15.1* Gy vs. 0.8 Gy), esophagus (20.7* Gy vs. 2.3 Gy) and pancreas (11.5* Gy vs. 0.0 Gy) 241 
while mean dose benefits between 5.0 to10.0 Gy were observed for the lenses (9.2* Gy vs. 242 
1.8 Gy), submandibular glands (7.9* Gy vs. 1.4 Gy), larynx and proximal esophagus (11.1* 243 
Gy vs. 2.3 Gy), heart (8.1* Gy vs. 0.0 Gy), lungs (8.3* Gy vs. 2.2 Gy), and intestines (9.6* 244 
Gy vs. 0.4 Gy) (Figure 3, Table 3).   245 
When comparing one specific radiotherapy technique among the three participating centers, 246 
a wide range in mean doses delivered to the OARs was found (Table 3). Ranges of >10.0 Gy 247 
were observed for the lenses (Tomotherapy), thyroid (VMAT, Tomotherapy), larynx + 248 
proximal esophagus (3D-CRT, VMAT, Tomotherapy, PBS), and esophagus (VMAT, 249 
Tomotherapy). Differences larger than 10Gy for D1cc between centers applying the same 250 
technique were even more frequent (Table 4).   Dmean ranges between 5.0 to 10.0 Gy were 251 
seen for the lenses (3D-CRT, VMAT, PBS), parotid and submandibular glands (3D-CRT, 252 
VMAT, PBS), thyroid (IMRT, PBS), heart (VMAT), intestines-stomach, pancreas and 253 
esophagus (VMAT, Tomotherapy), and kidneys (PBS). The range in mean doses for OARs of 254 
the spine was the narrowest for 3D-CRT.  255 
                                                   
∗
 Average of the Dmean median value of the three modern photon techniques 
For all photon techniques, 3D-CRT provided the smallest V1Gy, V2Gy and V5Gy of the TNTV 256 
but the highest V34.2Gy and V36Gy. Overlap in  TNTV dose was observed for the three 257 
modern photon techniques. The lowest TNTV dose was observed with PBS (Table 2). 258 
The largest inter-patient difference (maximum minus minimum value) found in Dmean for all 259 
OARs, considered in the manuscript, is 3 Gy (data not shown).  260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
Figure 3.  270 
Median Dmean (Gy) for the organs at risk surrounding the brain (A) and the spine (B). Error bars show the range 271 
(min, max) per technique  272 
[Tomo: Tomotherapy; PBS: proton pencil beam scanning]. 273 
 274 
 275 
 276 
 277 
 278 
Table 2.  Dosimetric parameters for PTVs and total normal tissue volume per technique 279 
 3D-CRT IMRT VMAT Tomo PBS 
 
Median  
[Range] 
Median  
[Range] 
Median 
[Range] 
Median 
[Range] 
Median 
[Range] 
PTV total dosimetry      
V95% (%) 
97.8 
[97.7-99.7] 
98.3 
[97.0-99.7] 
98.8 
[96.2-100.0] 
98.2 
[96.8-99.7] 
99.8 
[98.4-99.9] 
V107% (%) 
5.5 
[2.8-7.1] 
0.0 
[0.0-1.5] 
0.0 
[0.0-0.2] 
0.0 
[0.0-0.0] 
0.1 
[0.0-6.4] 
Dmean (Gy) 
36.4 
[36.1-37.2] 
36.7 
[36.0-36.8] 
35.9 
[35.7-36.1] 
35.9 
[35.8-36.0] 
36.0 
[36.0-36.1] 
D2% (Gy) 
39.4 
[38.8-40.5] 
37.8 
[37.1-38.4] 
37.3 
[37.1-37.6] 
36.6 
[36.5-36.8] 
37.7 
[36.4-39.8] 
D98% (Gy) 
34.1 
[34.1-34.9] 
34.3 
[33.8-34.8] 
34.4 
[33.8-35.4] 
34.3 
[33.7-35.0] 
35.2 
[34.3-35.3] 
CI 
0.6 
[0.5-0.6] 
0.7 
[0.6 -0.7] 
0.9 
[0.8-0.9] 
0.8 
[0.7-0.9] 
0.8 
[0.7-0.8] 
HI 
0.1 
[0.1-0.2] 
0.1 
[0.08-0.1] 
0.1 
[0.0-0.1] 
0.1 
[0.04-0.1] 
0.1 
[0.03-0.2] 
PTV brain dosimetry      
V95% (%) 
99.1 
[97.1-99.9] 
98.3 
[98.2-99.9] 
99.2 
[95.1-99.9] 
98.1 
[96.4-99.5] 
99.7 
[98.8-99.8] 
V107% (%) 
0.0 
[0.0-0.0] 
0.0 
[0.0-1.7] 
0.0 
[0.0-0.0] 
0.0 
[0.0-0.0] 
0.0 
[0.0-7.4] 
Dmean (Gy) 
36.3 
[35.6-37.2] 
36.9 
[36.0-37.0] 
35.9 
[35.6-36.1] 
35.9 
[35.8-36.0] 
36.1 
[36.0-36.1] 
D2% (Gy) 
37.2 
[36.8-38.1] 
37.8 
[37.1-38.5] 
37.4 
[37.1-37.6] 
36.6 
[36.5-36.8] 
37.2 
[36.4-40.0] 
D98% (Gy) 
34.9 
[34.0-35.4] 
34.4 
[34.2-35.3] 
34.5 
[33.7-35.5] 
34.3 
[33.5-35.0] 
35.2 
[34.4-35.2] 
CI 
0.8 
[0.7-0.8] 
0.8 
[0.8-1.0] 
0.9 
[0.8-0.9] 
0.9 
[0.8-0.9] 
0.9 
[0.7-0.9] 
HI 
0.1 
[0.06-0.1] 
0.1 
[0.07-0.1] 
0.1 
[0.0-0.1] 
0.1 
[0.0-0.1] 
0.1 
[0.0-0.2] 
PTV spine dosimetry      
V95% (%) 
99.3 
[94.0-99.3] 
98.2 
[94.2-99.1] 
99.7 
[97.9-99.9] 
99.5 
[98.8-99.6] 
99.8 
[98.2-99.9] 
V107% (%) 
20.7 
[10.6-27.1] 
0.2 
[0.0-0.4] 
0.0 
[0.0-0.3] 
0.0 
[0.0-0.0] 
0.2 
[0.0-3.7] 
Dmean (Gy) 
37.2 
[36.5-37.5] 
36.0 
[35.9-36.2] 
35.8 
[35.8-36.2] 
35.9 
[35.8-35.9] 
36.0 
[35.9-36.3] 
D2%  (Gy) 
40.3 
[39.7-42.4] 
37.8 
[37.0-38.5] 
37.3 
[37.3-37.6] 
36.6 
[36.5-36.6] 
38.2 
[36.4-39.6] 
D98% (Gy) 
34.6 
[33.2-34.6] 
34.4 
[34.3-34.5] 
34.2 
[33.7-35.2] 
34.9  
[34.7-34.9] 
35.2 
[34.2-35.7] 
CI 
0.3 
[0.3-0.4] 
0.6 
[0.5-0.6] 
0.8 
[0.6-0.8] 
0.5 
[0.5-0.7] 
0.6 
[0.5-0.7] 
HI 
0.2 
[0.1-0.2] 
0.1 
[0.08-0.1] 
0.1 
[0.06-0.1] 
0.0 
[0.0-0.1] 
0.1 
[0.0-0.2] 
TNTV      
V1Gy (%) 
52.6 
[46.1-56.1] 
66.1 
[64.9-79.6] 
70.2 
[63.7-75.5] 
69.5 
[62.5-71.7] 
15.4 
[11.3-20.1] 
V2Gy (%) 
35.9 
[33.-38.3] 
57.2 
[52.9-62.4] 
62.2 
[54.8-71.5] 
60.1 
[52.7-64.2] 
14.1 
[10.5-18.5] 
V5Gy (%) 
22.9 
[22.2-23.4] 
41.7 
[38.9-48.0] 
43.3 
[38.6-48.7] 
45.9 
[37.4-49.7] 
12.2 
[9.1-16.1] 
V34.2Gy (%) 
5.1 
[5.0-5.3] 
3.4 
[1.9-3.5] 
0.7 
[0.7-1.7] 
1.7 
[0.5-2.1] 
1.3 
[1.0-2.9] 
V36Gy (%) 
3.7 
[3.2-3.7] 
0.9 
[0.8-1.6] 
0.1 
[0.1-0.5] 
0.3 
[0.01-0.3] 
0.4 
[0.2-0.8] 
Vx% is the volume receiving at least x% of the prescribed dose 280 
Dx% is the dose received by x% of the volume 281 
VxGy is the volume receiving at least xGy of the prescribed dose 282 
CI is the conformity index 283 
HI is the homogeneity index 284 
 285 
 286 
 287 
Table 3. Dmean(Gy) for organs at risk with individual techniques  288 
Dmean OARs 3D-CRT IMRT VMAT Tomo PBS 
 
Median 
[Range] 
Median  
[Range] 
Median 
[Range] 
Median 
[Range] 
Median 
[Range] 
Scalp (Gy) 
31.2 
[29.8-31.3] 
32.3 
[28.0-32.9] 
28.1 
[28.0-29.0] 
30.9 
[27.9-32.9] 
27.8 
[26.3-34.0] 
Lens L (Gy) 
5.9 
[4.5-13.8] 
8.3 
[6.1-9.0] 
9.3 
[4.6-13.3] 
10.1 
[3.8-14.5] 
2.0 
[0.5-8.2] 
Lens R (Gy) 
5.8 
[3.9-9.9] 
8.0 
[4.3-8.2] 
8.6 
[4.8-12.7] 
11.1 
[3.8-15.0] 
1.7 
[0.4-7.7] 
Parotid gland L (Gy) 
23.5 
[19.0-28.4] 
20.8 
[19.4-22.2] 
10.4 
[9.7-15.1] 
13.1 
[12.2-15.0] 
4.0 
[1.3-10.5] 
Parotid gland R (Gy) 
17.4 
[16.3-28.2] 
20.6 
[19.7-22.7] 
11.3 
[10.1-15.4] 
12.9 
[12.0-14.4] 
4.0 
[0.8-9.7] 
Submandibular gland L (Gy) 
4.6 
[3.2-10.1] 
3.6 
[3.3-3.6] 
9.8 
[7.6-14.2] 
9.9 
[8.1-11.1] 
1.5 
[0.2-4.6] 
Submandibular gland R (Gy) 
5.0 
[3.1-12.6] 
3.4 
[3.4-3.5] 
10.8 
[7.8-13.6] 
10.3 
[8.4-11.2] 
1.3 
[0.6-6.3] 
Thyroid (Gy) 
28.5 
[25.7-29.3] 
17.0 
[13.6-19.4] 
13.0 
[5.6-24.6] 
15.3 
[7.0-19.7] 
0.8 
[0.3-10.1] 
Larynx + prox esophagus (Gy) 
9.8 
[9.0-24.9] 
10.7 
[9.7-11.6] 
13.3 
[5.5-26.0] 
9.3 
[7.8-19.5] 
2.3 
[1.9-17.9] 
Heart (Gy) 
13.4 
[13.1-14.0] 
8.1 
[8.0-8.3] 
6.9 
[5.7-10.9] 
9.4 
[7.7-11.9] 
0.01 
[0.01-0.2] 
Lung L (Gy) 
4.1 
[3.6-4.2] 
7.0 
[6.5-8.2] 
7.9 
[7.8-9.7] 
6.9 
[6.5-7.1] 
2.0 
[1.3-4.9] 
Lung R (Gy) 
8.6 
[7.9-8.8] 
8.6 
[8.5-9.5] 
10.2 
[8.3-10.3] 
9.4 
[7.9-10.7] 
2.3 
[2.0-5.8] 
Esophagus (Gy) 
29.9 
[29.7-31.3] 
19.4 
[18.8-20.5] 
16.3 
[12.2-23.6] 
26.5 
[21.6-31.9] 
2.3 
[0.7-6.8] 
Intestines (Gy) 
10.1 
[9.9-10.2] 
8.7 
[8.3-8.7] 
8.4 
[6.6-12.0] 
11.7 
[7.7-12.0] 
0.4 
[0.1-0.5] 
Pancreas (Gy) 
17.1 
[16.4-17.6] 
12.1 
[10.2-13.3] 
8.7 
[8.5-15.4] 
13.7 
[8.2-14.7] 
0.0 
[0.0-0.0] 
Kidney L (Gy) 
4.5 
[4.2-4.8] 
6.2 
[5.2-9.8] 
7.5 
[5.8-9.0] 
6.3 
[5.7-6.8] 
2.5 
[0.9-7.7] 
Kidney R (Gy) 
3.3 
[3.0-3.9] 
5.3 
[5.0-8.9] 
5.6 
[5.6-8.4] 
6.1 
[4.9-6.5] 
2.3 
[2.0-5.8] 
* Differences per technique >10.0 Gy or between 5.0- 10.0 Gy are indicated in bold or italic, respectively.  289 
 290 
 291 
 292 
 293 
 294 
 295 
 296 
 297 
 298 
 299 
 300 
 301 
Table 4. D1cc (Gy) for organs at risk with individual techniques  302 
D1cc OARs 3D-CRT IMRT VMAT Tomo PBS 
 
Median 
[Range] 
Median  
[Range] 
Median 
[Range] 
Median 
[Range] 
Median 
[Range] 
Scalp (Gy) 
37.1 
[36.2-38.0] 
37.1 
[36.8-37.8] 
36.0 
[35.3-37.5] 
36.0 
[35.3-36.3] 
36.9 
[35.8-37.7] 
Lens L (Gy) 
9.4 
[6.2-21.8] 
13.7 
[13.0-13.8] 
10.8 
[5.3-17.0] 
11.7 
[4.6-16.9] 
3.7 
[1.6-10.8] 
Lens R (Gy) 
13.7 
[5.2-20.8] 
15.8 
[15.2-16.0] 
10.3 
[5.6-17.2] 
12.9 
[4.5-17.1] 
3.6 
[1.2-10.9] 
Parotid gland L (Gy) 
36.5 
[35.9-37.5] 
36.5 
[35.8-36.7] 
19.2 
[18.9-23.6] 
23.6 
[23.2-25.1] 
16.1 
[14.4-31.1] 
Parotid gland R (Gy) 
36.2 
[36.0-37.4] 
36.4 
[36.0-37.7] 
20.8 
[19.8-24.6] 
22.7 
[22.0-24.9] 
13.3 
[9.9-28.6] 
Submandibular gland L (Gy) 
9.1 
[5.1-19.0] 
4.7 
[3.6-8.4] 
17.0 
[12.7-19.6] 
13.7 
[10.9-15.0] 
10.9 
[1.6-15.1] 
Submandibular gland R (Gy) 
17.6 
[4.2-19.4] 
6.8 
[6.4-10.5] 
14.9 
[14.5-19.7] 
14.2 
[12.1-15.6] 
9.5 
[4.2-23.0] 
Thyroid (Gy) 
30.7 
[29.4-30.8] 
26.1 
[20.7-27.7] 
17.9 
[14.5-30.1] 
24.2 
[13.6-28.6] 
7.4 
[5.6-25.8] 
Larynx + prox esophagus (Gy) 
31.7 
[30.2-31.8] 
30.1 
[24.3-32.1] 
20.2 
[14.8-33.5] 
24.7 
[12.5-30.4] 
17.5 
[11.2-33.5] 
Heart (Gy) 
29.1 
[28.5-29.9] 
15.1 
[14.9-18.6] 
11.7 
[10.9-16.9] 
17.4 
[14.0-24.4] 
0.3 
[0.2-3.5] 
Lung L (Gy) 
33.0 
[31.3-33.8] 
27.8 
[25.8-30.4] 
27.2 
[25.3-27.6] 
29.9 
[25.1-31.1] 
28.5 
[26.4-33.7] 
Lung R (Gy) 
33.1 
[32.4-35.7] 
28.3 
[26.1-30.6] 
28.4 
[25.4-28.8] 
29.3 
[27.6-33.0] 
28.1 
[27.8-33.6] 
Esophagus (Gy) 
32.4 
[31.2-37.1] 
32.1 
[26.3-38.9] 
22.6 
[18.9-32.3] 
28.5 
[26.5-31.1] 
13.6 
[6.5-26.8] 
Intestines (Gy) 
31.0 
[28.8-32.3] 
23.9 
[23.1-24.7] 
17.7 
[17.3-26.3] 
27.4 
[22.1-29.9] 
11.4 
[1.0-16.2] 
Pancreas (Gy) 
28.6 
[27.5-39.4] 
19.8 
[15.5-23.9] 
13.2 
[11.0-21.9] 
21.4 
[10.3-24.7] 
0.1 
[0.1-0.3] 
Kidney L (Gy) 
33.3 
[32.7-33.3] 
24.2 
]19.2-28.8] 
23.3 
[14.9-25.9] 
21.8 
[21.0-26.6] 
23.7 
[20.3-34.3] 
Kidney R (Gy) 
31.8 
[29.4-32.3] 
21.7 
[21.0-27.7] 
21.8 
[19.7-23.0] 
22.5 
[21.8-27.9] 
23.2 
[14.5-33.8] 
* Differences per technique >10.0 Gy or between 5.0- 10.0 Gy are indicated in bold or italic, respectively.  303 
 304 
 305 
 306 
307 
DISCUSSION  308 
This multicenter dosimetric comparison of five different radiotherapy techniques (3D-CRT, 309 
IMRT, VMAT,  Tomotherapyand PBS) currently applied for CSI demonstrates improved dose 310 
conformity and homogeneity of the target volume with all modern radiotherapy techniques 311 
compared with 3D-CRT, as well as a reduction in mean dose of >5.0 Gy to organs such as 312 
the thyroid, heart, esophagus, and pancreas. Compared to IMRT, VMAT, and  Tomotherapy, 313 
an additional decrease in mean dose (>5.0 Gy) is found with PBS for lenses, parotid- and 314 
submandibular glands, larynx, thyroid, lungs, heart, intestines, stomach and pancreas. 315 
However, caution is needed in the interpretation of these results since ranges in mean dose 316 
for a number of OARs are wide per technique and also overlapping between different 317 
techniques. For example, the mean thyroid dose can range between 5.6 Gy and 24.6 Gy 318 
with VMAT and between 0.3 Gy and 10.1 Gy with PBS, depending on the treatment center. 319 
In the literature several reports demonstrate improved CI and HI for the PTV and field-320 
junctions by the use of modern radiotherapy techniques compared with 3D-CRT 321 
[11,13,17,35,36]. However, it should be mentioned that knowledge on the uncertainties 322 
related to possible motion of the target and correct target volume delineation are pre-323 
requisites for highly-conformal techniques. The latter becomes relevant at the meningeal 324 
surfaces and cerebrospinal fluid in the dural reflections of the cranial nerves [37, 38].  325 
In clinical practice, the reason for using more conformal techniques is better sparing of 326 
healthy tissue outside the planning target volume. However, nearly all published data on 327 
late toxicity after CSI concern neuro-cognitive decline, endocrinopathies, or growth 328 
retardation, in fact problems inherent to the treatment of the target volume [18-21]. In 329 
contrast, fewer results have been published on late toxicity outside the craniospinal target 330 
volume despite the use of the conventional 3D-CRT for decades [27-32]. As the introduction 331 
of modern radiotherapy techniques is of more recent date, it is still too early to be able to 332 
demonstrate a clinical benefit due to better sparing of the OARs surrounding the 333 
craniospinal PTV. Nevertheless, for the thyroid, heart, lung, and pancreas, it may be 334 
relevant to improve organ sparing even at relatively low dose levels [21,29-32]. 335 
Techniques like IMRT, VMAT and  Tomotherapy have the potential to decrease the dose to 336 
the thyroid, heart, esophagus and pancreas compared with 3D-CRT at the cost of a higher 337 
integral dose and therefore a higher potential risk of second malignancies induction. For this 338 
reason, an higher TNTV dose with modern photon techniques is often used as the argument 339 
for 3D-CRT continuation. Proton beam therapy is therefore very attractive, as it offers both 340 
high conformity and reduction of integral dose. In the literature several papers report on the 341 
estimated risk for secondary malignancies based on empirical models [e.g. 39]. However, 342 
the authors believe that this risk estimation should be based on clinical data. Unfortunately, 343 
very little clinical information on dose dependency for second malignancy induction is 344 
available. With a median follow-up of ten years, two reports on second malignancies after 345 
3D-CRT have suggested tumor induction mainly within or adjacent to the PTV [27,28]. 346 
Therefore, it is uncertain whether a significant increase in second malignancies will be 347 
observed due to low dose irradiation to structures anterior to the vertebrae with modern 348 
photon techniques. However, although studies did not show that the unintended dose 349 
outside the target volume causes clinically significant side effects including secondary 350 
cancer, attempts should be made to keep dose to the OARs as low as possible. The same is 351 
true when administering protons by maximally limiting the scattered contribution from 352 
secondary neutrons, i.e. by preferably using PBS technology rather than passive scattered 353 
beams [40]. Additional reasons to refer patients for proton therapy are further dosimetric 354 
reductions in mean dose to  the organs at risk compared to modern photon techniques. 355 
However, it might be questioned whether any clinical benefit will be observed if the doses 356 
received by the organs at risk remain far below the expected normal tissue tolerances 357 
[21,31, 41, 42]. Although the dosimetric outcome of this work is in favor of proton therapy 358 
and to a lesser extent of modern photon techniques, significant range in mean doses (up to 359 
20 Gy) to the OARs are found between centers using a similar technique. This inter-center 360 
variation in mean doses to the OARs is larger than the differences in OARs doses reported 361 
by other published studies comparing irradiation techniques [12, 14, 35, 36].  On one hand, 362 
the large dose range  points towards an effect of mastering a technique to a different 363 
extent, as already observed for VMAT dose distributions by Fogliata et al. [43]. On the other 364 
hand, these differences can be attributed to the choice of the optimization criteria made by 365 
the centers, prioritizing one objective over another (Table S1). For this planning study no 366 
fixed list of constraints for the OARs was provided to the participants in order to reflect daily 367 
practice in different centers using similar techniques. This means that in absence of an 368 
international guideline on dose-constraints for OARs related to CSI, a significant dose-range 369 
will persist between centers using similar techniques. However, this observation  also 370 
impacts the potential benefit of one technique compared to another. Knowledge based 371 
planning systems could help reducing the differences in OAR sparing between  institutions 372 
and techniques [44, 45]. 373 
  As no consensus on dose constraints to vertebral bodies does exist at present time, an 374 
adolescent patient was chosen for this study to avoid discussions related to growth 375 
problems between centers. Including the vertebrae in the target volume will increase the 376 
dose to the structures antero-lateral of the vertebral bodies to some extent. However, it is 377 
not expected that the observations/conclusions from this study will alter by additional dose 378 
steering on the vertebrae. In addition, selecting an adolescent patient with a larger spinal 379 
target volume is technically more challenging. 380 
Although we are aware of the fact that this work is based on the analysis of one patient 381 
only, we do not expect that expanding the number of patients will change our findings given 382 
the fact that the CSA target volume is quite consistent in between patients, and in relation 383 
to the surrounding structures [46]. The widest range of OARs mean doses for five different 384 
patients planned by VMAT at our department was 3 Gy. The latter value is smaller than the 385 
variation observed for some OARs in between centers using the same technique or in 386 
between techniques. This observation supports the methodology of the study to focus on 387 
one patient for assessing inter-center variation as it reflects the daily reality for one patient.    388 
The variation in dosimetry could be reduced if the treatment planning exercise would have 389 
been repeated using the same constraints for all centers, as already demonstrated by 390 
Verbakel et al. [47],  However, this re-optimization of the treatment planning technique 391 
does not reflect current situations across different centers and techniques.    392 
For comparison purposes the same PTV margin was used for all techniques. We 393 
acknowledge that this uncertainty margin is inherent to a technique, equipment, and 394 
institutional protocols (e.g. patient immobilization methods, patient setup error correction 395 
protocols) [48]. Locally adopted PTV margins will have a potential impact on OARs dose in 396 
proximity of the target volume. However, it is expected that the found dosimetric range per 397 
institution and per technique will persist. Furthermore, the effect of patient (re)positioning 398 
uncertainties on the dose distribution has not been taken into account in this analysis. In 399 
fact, one technique might be more robust than another resulting in smaller detrimental 400 
effects on the ideal static dose distribution calculated by the treatment planning system 401 
[49-51]. Comparing the robustness of the different techniques is part of a future work. 402 
Finally, this is an in-silico treatment planning study and it has been demonstrated that a 403 
robust in-silico planning study may overestimate the potential dosimetric benefits of one 404 
technique over another [52,53].  405 
 406 
  407 
CONCLUSION 408 
Compared with 3D-CRT, modern radiotherapy techniques demonstrate a superior dose 409 
distribution often at the cost of a higher integral dose. With protons a further dosimetric 410 
reduction is observed for the OARs and integral body dose. Nevertheless, a wide range of 411 
doses to the OARs is found even between centers using similar techniques. In addition, an 412 
international guideline with dose constraints for CSI is essential to ensure comparable 413 
outcome between different centers.  414 
 415 
 416 
 417 
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SUPPLEMENTARY MATERIAL 578 
 579 
Table S1. Overview of the constraints used for the OARs per technique, and per center. 580 
 581 
 Center 3D-CRT IMRT VMAT Tomotherapy PBS 
Thyroid 1 
2 
3 
No limit 
No limit 
No limit 
Max EUD <12 Gy 
No limit 
No limit 
Dmean <5-10 Gy 
No limit 
No limit 
Dmax < 15 Gy 
Dmean < 19.5 Gy 
Dmean ~6-20Gy 
No limit 
No limit 
No limit 
Larynx 1 
2 
3 
No limit 
No limit 
No limit 
Max EUD <10 Gy 
No limit 
No limit 
Dmean <5-10 Gy 
No limit 
No limit 
Dmax < 15 Gy 
No limit 
No limit 
No limit 
No limit 
No limit 
Heart 1 
2 
3 
No limit 
No limit 
No limit 
Max dose <20 Gy 
No limit 
No limit 
Dmean <5-8 Gy 
No limit 
No limit 
Dmax < 15 Gy 
Dmean < 14 Gy 
Dmean ~6-11Gy 
No limit 
No limit 
No limit 
Lungs 1 
2 
3 
No limit 
No limit 
No limit 
Max DVH 5% <20Gy 
No limit 
No limit 
Dmean <5-10 Gy 
No limit 
No limit 
Dmax < 34 Gy 
Dmean < 12 Gy 
Dmean ~6-11Gy 
No limit 
No limit 
No limit 
Oesophagus 1 
2 
3 
No limit 
No limit 
No limit 
Max EUD <10 Gy 
No limit 
No limit 
Dmean < 14 Gy 
No limit 
No limit 
No limit 
Dmean < 33 Gy 
Dmean ~10-20Gy 
No limit 
No limit 
No limit 
Intestine+stomach      1 
     2 
3 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
Dmax < 30 Gy 
V40Gy < 100 % 
No limit 
No limit 
No limit 
No limit 
Pancreas 1 
2 
3 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
Kidneys 1 
 
2 
3 
No limit 
 
No limit 
No limit 
Max DVH 5% <20Gy 
V20 aim < 25%, accept < 35% 
No limit 
No limit 
Dmean <5-8 Gy 
 
No limit 
No limit 
Dmax < 34 Gy 
 
Dmean < 10 Gy 
Dmean ~4-7Gy 
No limit 
No limit 
No limit 
No limit 
Sclap 1 
2 
     3 
No limit 
No limit 
No limit 
Max EUD <12 Gy 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
No limit 
Lens 1 
2 
     3 
No limit 
No limit 
Dmean<10Gy 
Max EUD <10 Gy 
No limit 
No limit 
Dmean < 12-14 Gy 
No limit 
No limit 
Dmax <4.5 Gy 
Dmean < 6 Gy 
Dmean < 28 Gy 
Dmax< 10Gy 
Dmean < 8Gy 
No limit 
Parotid glands 1 
2 
3 
No limit 
No limit 
No limit 
Max dose <20 Gy 
No limit 
No limit 
Dmean <5-10 Gy 
No limit 
No limit 
Dmax < 25 Gy 
Dmean < 12 Gy 
No limit 
No limit 
No limit 
No limit 
Submandibularis 
glands 
1 
2 
3 
No limit 
No limit 
No limit 
Max DVH 5% <20Gy 
No limit 
No limit 
Dmean <5-10 Gy 
No limit 
No limit 
No limit 
Dmean < 12 Gy 
No limit 
No limit 
No limit 
No limit 
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 593 
Figure S1. Dmean (Gy) for the organs at risk surrounding the brain and the spine per 594 
technique and per center. 595 
[Tomo: Tomotherapy; PBS: proton pencil beam scanning]. 596 
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 640 
LEGEND OF THE FIGURES 641 
 642 
Figure 1 643 
 644 
Craniospinal axis dose distribution with photons (3D-CRT, IMRT, VMAT, Tomotherapy) and 645 
protons. Only one out of three generated plans per technique is depicted.  646 
 647 
Figure 2:  648 
CI, HI, D2% and D98% of the PTVbrain and PTVspine  per center and per technique 649 
[Tomo: Tomotherapy; PBS: proton pencil beam scanning]. 650 
 651 
Figure 3:  652 
Median Dmean (Gy) for the organs at risk surrounding the brain (A) and the spine (B). Error 653 
bars show the range (min, max) per technique  654 
[Tomo: Tomotherapy; PBS: proton pencil beam scanning]. 655 
 656 
Figure S1: 657 
Dmean (Gy) for the organs at risk surrounding the brain and the spine per technique and per 658 
center. 659 
[Tomo: Tomotherapy; PBS: proton pencil beam scanning]. 660 
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